Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL-1

Eur Respir J. 2022 Jun 23;59(6):2102577. doi: 10.1183/13993003.02577-2021. Print 2022 Jun.

Abstract

Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL−1). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb

Trial registration: ClinicalTrials.gov NCT02414854.

Publication types

  • Letter

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / drug therapy
  • Eosinophils
  • Humans

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • dupilumab

Associated data

  • ClinicalTrials.gov/NCT02414854